182
(A,T,G,C) of life. The answer to many human aliments lie within these microbial
genes; what is required is a well-planned and structured interplay between researchers from various fields like genetics, bioinformatics, chemistry, and molecular biology to tap the potential from this genomic information available.
References
Alberts DS, Garcia D, Mason-Liddil N (1991) Cisplatin in advanced cancer of the cervix: an
update. Semin Oncol 18:11–24
Asolkar RN, Maskey RP, Helmke E, Laatsch H (2002) Chalcomycin B, a new macrolide antibiotic
from the marine isolate Streptomyces sp. B7064. J Antibiot 55:893–898
Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52:3119–3124
Becerro MA, Goetz G, Paul VJ, Scheuer PJ (2001) Chemical defenses of the sacoglossan mollusk
Elysia rufescens and its host alga Bryopsis sp. J Chem Ecol 27:2287–2299
Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, Stadler WM (1999) In
vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer.
Urology 154:573–577
Berdy J (2005) Bioactive microbial metabolites. J Antibiot 58:1–26
Betz C, Hall MN (2013) Where is mTOR and what is it doing there? J Cell Biol 203:563–574
Bruns RF, Miller FD, Merriman RL, Howbert JJ, Heath WF, Kobayashi E, Takahashi I, Tamaoki
T, Nakano H (1991) Inhibition of protein kinase C by calphostin C is light-dependent. Biochem
Biophys Res Commun 176:288–293
Cardenas ME, Sanfridson A, Cutler NS, Heitman J (1998) Signal-transduction cascades as targets
for therapeutic intervention by natural products. Trends Biotechnol 16:427–433
Carte BK (1966) Biomedical potential of marine natural products. Bioscience 46:271–286
Cheng YQ, Tang GL, Shen B (2003) Type I polyketide synthase requiring a discrete acyltransferase for polyketide biosynthesis. Proc Natl Acad Sci U S A 100:3149–3154
Chiarini A, Whitfield JF, Armato U, Dal Pra I (2006) VP-16 (etoposide) and calphostin C trigger different nuclear but akin cytoplasmic patters of changes in the distribution and activity
of protein kinase C-ßI in polyomavirus-transformed pyF111 rat fibroblasts. Int J Mol Med
17:111–120
Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239–242
Cox AD, Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Biochim Biophys Acta 1333:51–71
Dal Pra I, Whitfield JF, Chiarini A, Armato U (2000) Increased activity of the protein kinase-‰
holoenzyme in the cytoplasmic particulate fraction precedes activation of caspases in the polyomavirus- transformed pyF111 rat fibroblasts exposed to calphostin C or topoisomerase II
inhibitors. Exp Cell Res 255:171–183
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz
MA, Yuan J (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for
ischemic brain injury. Nat Chem Biol 1:112–119
Diwu Z, Lown JW (1993) Photosensitization with anticancer agents. 15. Perylenequinoid pigments as potential photodynamic therapeutic agents: formation of semiquinone radicals and
reactive oxygen species on illumination. J Photochem Photobiol 18:131–143
Ferrer M, Beloqui A, Timmis KN, Golyshin PN (2009) Metagenomics for mining new genetic
resources of microbial communities. J Mol Microbiol Biotechnol 16:109–123
Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell
cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation
initiation factor 4E. Mol Cell Biol 24:200–216
V.M. Dan and R. Sanawar
(A,T,G,C) of life. The answer to many human aliments lie within these microbial
genes; what is required is a well-planned and structured interplay between researchers from various fields like genetics, bioinformatics, chemistry, and molecular biology to tap the potential from this genomic information available.
References
Alberts DS, Garcia D, Mason-Liddil N (1991) Cisplatin in advanced cancer of the cervix: an
update. Semin Oncol 18:11–24
Asolkar RN, Maskey RP, Helmke E, Laatsch H (2002) Chalcomycin B, a new macrolide antibiotic
from the marine isolate Streptomyces sp. B7064. J Antibiot 55:893–898
Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52:3119–3124
Becerro MA, Goetz G, Paul VJ, Scheuer PJ (2001) Chemical defenses of the sacoglossan mollusk
Elysia rufescens and its host alga Bryopsis sp. J Chem Ecol 27:2287–2299
Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, Stadler WM (1999) In
vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer.
Urology 154:573–577
Berdy J (2005) Bioactive microbial metabolites. J Antibiot 58:1–26
Betz C, Hall MN (2013) Where is mTOR and what is it doing there? J Cell Biol 203:563–574
Bruns RF, Miller FD, Merriman RL, Howbert JJ, Heath WF, Kobayashi E, Takahashi I, Tamaoki
T, Nakano H (1991) Inhibition of protein kinase C by calphostin C is light-dependent. Biochem
Biophys Res Commun 176:288–293
Cardenas ME, Sanfridson A, Cutler NS, Heitman J (1998) Signal-transduction cascades as targets
for therapeutic intervention by natural products. Trends Biotechnol 16:427–433
Carte BK (1966) Biomedical potential of marine natural products. Bioscience 46:271–286
Cheng YQ, Tang GL, Shen B (2003) Type I polyketide synthase requiring a discrete acyltransferase for polyketide biosynthesis. Proc Natl Acad Sci U S A 100:3149–3154
Chiarini A, Whitfield JF, Armato U, Dal Pra I (2006) VP-16 (etoposide) and calphostin C trigger different nuclear but akin cytoplasmic patters of changes in the distribution and activity
of protein kinase C-ßI in polyomavirus-transformed pyF111 rat fibroblasts. Int J Mol Med
17:111–120
Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239–242
Cox AD, Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Biochim Biophys Acta 1333:51–71
Dal Pra I, Whitfield JF, Chiarini A, Armato U (2000) Increased activity of the protein kinase-‰
holoenzyme in the cytoplasmic particulate fraction precedes activation of caspases in the polyomavirus- transformed pyF111 rat fibroblasts exposed to calphostin C or topoisomerase II
inhibitors. Exp Cell Res 255:171–183
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz
MA, Yuan J (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for
ischemic brain injury. Nat Chem Biol 1:112–119
Diwu Z, Lown JW (1993) Photosensitization with anticancer agents. 15. Perylenequinoid pigments as potential photodynamic therapeutic agents: formation of semiquinone radicals and
reactive oxygen species on illumination. J Photochem Photobiol 18:131–143
Ferrer M, Beloqui A, Timmis KN, Golyshin PN (2009) Metagenomics for mining new genetic
resources of microbial communities. J Mol Microbiol Biotechnol 16:109–123
Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell
cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation
initiation factor 4E. Mol Cell Biol 24:200–216
V.M. Dan and R. Sanawar